CURRICULUM VITAE

Name:	Mark L. Brantly
Date and Place of Birth:	……..
Citizenship:	United States
Education:	
1976 B. S.	Florida State University
	Tallahassee, Florida
1979 M.D.	University of Florida
	Gainesville, Florida
Licensure:	Virginia …….
	North Carolina …….
	Florida ……..
Board Certification:	American Board of Internal Medicine 1982
	Pulmonary Medicine 1994
Chronology of Employment:	
2000-	Associate Director University of Florida GCRC
	Gainesville, Florida
1996-2000	Board of Directors Alphal Foundation
	Coconut Grove, Florida
1996-2001	Co-Chair, Alphal Research Centers Network
	Coconut Grove, Florida
1998-	Professor of Medicine, Molecular Genetics, and Microbiology
	Division of Pulmonary and Critical Care Medicine
	University of Florida College of Medicine
1998-	Director, OF al-Antitrypsin Genetics Laboratory
	University of Florida College of Medicine
1995-1998	Senior Investigator and
	Head, Pulmonary Function Laboratory
	Pulmonary-Critical Care Medicine Branch
	National Heart, Lung, and Blood Institute
	Bethesda, Maryland
1995-1998	Reviewer
	National Heart, Lung, and Blood Institute
	Mammalian Genotyping Service

Center for Medical Genetics

Marshfield Medical Research Foundation
Marshfield, Wisconsin

1990-1994 Head, Unit on Genetic Disorders of Secreted Proteins
Human Genetics Branch

National Institute of Child Health and Human Development
Bethesda, Maryland

1990-1994 NICHD-1RB Committee Member

National Institute of Child Health and Human Development
Bethesda, Maryland

1988-1998 Director, National al-Antitrypsin Phenotyping Laboratory
Pulmonary-Critical Care Medicine Branch National Heart, Lung, and Blood Institute Bethesda, Maryland

1988-1997 National Heart, Lung, and Blood Institute al-Antitrypsin Deficiency Registry Steering Committee Member

1989-1990 Senior Staff Fellow Pulmonary Branch
National Heart, Lung and Blood Institute
Bethesda, Maryland

1986-1989 Parker B. Francis Fellow Pulmonary Branch
National Heart, Lung, and Blood Institute
Bethesda, Maryland

1983-1986 Senior Staff Fellow Pulmonary Branch
National Heart, Lung, and Blood Institute
Bethesda, Maryland

1982-1983 Chief Medical Resident Eastern Virginia
Medical School Norfolk, Virginia

1980-1982 Residency, Internal Medicine

Eastern Virginia Medical School Norfolk, Virginia 1979-1980 Internship

Eastern Virginia Medical School Norfolk, Virginia

Honors:

1978-1979 Student Director, Family Practice Program University of Florida

1979 Paul Elliot Award for Excellence in Primary Care

1986-1989 Parker B. Francis Research Fellow in Pulmonary Medicine

1995 Alpha l National Association Award

1996-1997 Visiting Professor Award Universita Degli Studi Di Modena

1998- Alpha One Foundation Research Professorship

Professional Societies: American Thoracic Association American Society of Cell Biology

Publications

1. Chaudhuri, T. K. and M. Brantly. "Heparin as a pharmacologic intervention to induce positive scintiscan in occult gastrointestinal bleeding." Clin Nucl Med. 9(4): 187-8, 1984.

2 Garver, R. J., J. F. Mornex, T. Nukiwa, M. Brantly, M. Courtney, J. P. LeCocq and R. G. Crystal. "Alpha 1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing alpha 1-antitrypsin genes." N Engl J Med. 314(12): 762-6, 1986.

3. Miskulin, M., R. Dalgleish, B. B. Kluve, S. I. Rennard, P. Tolstoshev, M. Brantly and R. G. Crystal. "Human type III collagen gene expression is coordinately modulated with the type I collagen genes during fibroblast growth." Biochemistry. 25(6): 1408-13, 1986.

4. Nukiwa, T., M. Brantly, R. Garver, L. Paul, M. Courtney, J. P. LeCocq and R. G. Crystal. "Evaluation of "at risk: alpha 1-antitrypsin genotype SZ with synthetic oligonucleotide gene probes." J Clin Invest. 77(2): 528-37, 1986.

5. Nukiwa, T., K. Satoh, M. L. Brantly, F. Ogushi, G. A. Fells, M. Courtney and R. G. Crystal. "Identification of a second mutation in the protein-coding sequence of the Z type alpha 1-antitrypsin gene. J Biol Chem. 261(34): 15989-94, 1986.

6. Garver, R. J., A. Chytil, S. Karlsson, G. A. Fells, M. L. Brantly, M. Courtney, P. W. Kantoff, A. W. Nienhuis, W. F. Anderson and R. G. Crystal. "Production of glycosylated physiologically "normal: human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector." Proc Natl Acad Sci U S A. 84(4): 10504,1987.

7. Nukiwa, T., M. Brantly, F. Ogushi, G. Fells, K. Satoh, L. Stier, M. Courtney and R. G. Crystal. "Characterization of the M1(Ala213) type of alpha 1-antitrypsin, a newly recognized, common "normal: alpha 1-antitrypsin haplotype." Biochemistry. 26: 5259-67, 1987.

8. Nukiwa, T., H. Takahashi, M. Brantly, M. Courtney and R. G. Crystal. "alpha 1-Antitrypsin nullGranite Falls, a nonexpressing alpha 1-antitrypsin gene associated with a frameshift to stop mutation in a coding exon." J Biol Chem. 262(25): 11999-2004, 1987.

9. Wewers, M. D., M. L. Brantly, M. A. Casolaro and R. G. Crystal. "Evaluation of tamoxifen as a therapy to augment alpha- l -antitrypsin concentrations in Z homozygous alpha- l -antitrypsindeficient subjects." Am Rev Respir Dis. 135(2):401-2,1987.

10. **Brantly, M., T. Nukiwa and R. G. Crystal. "Molecular basis of alpha- l-antitrypsin deficiency." Am J Med. 84(6A): 13-31, 1988.**

11. **Brantly, M., M. Courtney and R. G. Crystal. "Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation." Science. 242(4886): 1700-2, 1988.**

12. **Brantly, M. L., L. D. Paul, B. H. Miller, R. T. Falk, M. Wu and R. G. Crystal. "Clinical**

features and history of the destructive lung disease associated with alpha- l-antitrypsin deficiency of adults with pulmonary symptoms." Am Rev Respir Dis. 138(2):327-36,1988.

13. Nukiwa, T., M. L. Brantly, F. Ogushi, G. A. Fells and R. G. Crystal. "Characterization of the gene and protein of the common alpha 1-antitrypsin normal M2 allele." Am J Hum Genet. 43(3): 322-30, 1988.

14. Satoh, K., T. Nukiwa, M. Brantly, R. J. Garver, M. Hoficer, M. Courtney and R. G. Crystal. "Emphysema associated with complete absence of alpha 1- antitrypsin in serum and the homozygous inheritance of a stop codon in an alpha 1-antitrypsin-coding exon Am J Hum Genet. 42(1): 77-83, 1988.

15. Takahashi, H., T. Nukiwa, K. Satoh, F. Ogushi, M. Brantly, G. Fells, L. Stier, M. Courtney and R. G. Crystal. "Characterization of the gene and protein of the alpha 1-antitrypsin "deficiency: allele Mprocida." J Biol Chem. 263(30): 15528-34, 1988.

16. Ogushi, F., R. C. Hubbard, G. A. Fells, M. A. Casolaro, D. T. Curiel, M. L. Brantly and R. G. Crystal. "Evaluation of the S-type of alpha- l -antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase." Am Rev Respir Dis. 137(2):364-70,1988.

17. Curiel, D., M. Brantly, E. Curiel, L. Stier and R. G. Crystal. "Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1antitrypsin gene incapable of producing alpha 1-antitrypsin . J Clin Invest. 83(4): 1144-52, 1989.

18. Okayama, H., M. D. Holmes, M. L. Brantly and R. G. Crystal. "Characterization of the coding sequence of the normal M4 alpha 1-antitrypsin gene." Biochem Biophys Res Commun. 162(3): 1560-70, 1989.

19. Okayama, H., D. T. Curiel, M. L. Brantly, M. D. Holmes and R. G. Crystal. "Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification." J Lab Clin Med. 114(2): 105-13, 1989.

20. Hubbard, R. C., M. L. Brantly, S. E. Sellers, M. E. Mitchell and R. G. Crystal. "Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin." Ann Intern Med. 111(3): 206-12, 1989.

21. Crystal, R. G., M. L. Brantly, R. C. Hubbard, D. T. Curiel, D. J. States and M. D. Holmes. "The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy." Chest 95(1): 196-208, 1989.

22. Curiel, D. T., M. D. Holmes, H. Okayama, M. L. Brantly, C. Vogelmeier, W. D. Travis, L. E. Stier, W. H. Perks and R. G. Crystal. "Molecular basis of the liver and lung disease associated with the alpha 1-antitrypsin deficiency allele Mmalton." J Biol Chem. 264(23): 13938-45, 1989.

23. Holmes, M., D. Curiel, M. Brantly and R. G. Crystal. "Characterization of the intracellular mechanism causing the alpha- l-antitrypsin nullgranite falls deficiency state." Am Rev Respir Dis

140(6): 1662-7, 1989.

24. Holmes, M. D., M. L. Brantly, G. A. Fells and R. G. Crystal. "Alpha 1-antitrypsin Wbethesda: molecular basis of an unusual alpha 1-antitrypsin deficiency variant." Biochem Biophys Res Commun 170(3):1013-20,1990.

25. Holmes, M. D., M. L. Brantly, D. T. Curiel, S. Weidinger and R. G. Crystal. "Characterization of the normal alpha 1-antitrypsin allele Vmunich: a variant associated with a unique protein isoelectric focusing pattern." Am J Hum Genet. 46(4): 810-6, 1990.

26. Holmes, M. D., M.L. Brantly, and R.G. Crystal. Molecular analysis of the heterogeneity among the P-Tamily of alpha- l-antitrypsin alleles. Am Rev Respir Dis. 142: 1185-1192, 1990.

27. Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG. Accurate quantification of serum al-antitrypsin standard to establish ranges for the common normal and deficient al-antitrypsin phenotypes. Chest 100: 703-708, 1991 .

28. Okayama H, Brantly ML, Holmes M, Crystal RG. Characterization of the Molecular Basis of the a1-Antitrypsin F Allele. Am J Hum Gen 48: 1154-1158, 1991.

29. Saltini C and Brantly ML. Distuzione polmonare da deficenza di alfa 1-antitripsina: correlazioni tra cuore e polmone. Congengo Internazionale su Fisiopatologia-Clinica Cardiovascolare e Respiratoria, Il Cigno Galileo Galilei Edizioni di Arte e Scienza, Roma p 81-94, 1992.

30. Brantly ML. Diagnosis and treatment of al-antitrypsin deficiency. The Endocrinologist 2: 33-39, 1992.

31. Hildesheim J, Kinsley G, Bissell M, Pierce J, and Brantly M. Genetic diversity from a limited repertoire of mutations on different common allelic backgrounds: al-antitrypsin deficiency variant Pduarte. Human Mutation 2: 221-228, 1993.

32. Laubach V, Hildesheim J, Ryan WJ, Brantly M. Characterization of a human al-antitrypsin Null allele involving aberrant mRNA splicing. Hum Mol Genetics 2: 1001-1005, 1993.

33. Saltini C, Brantly M. and Richeldi, L. Biologia molecolare dell'albero respiratorio. 1993 Ital Society of Resp. Pathophys.

34. Blank, C. A., Brantly, M. Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. Ann Allergy 72: 105-120, 1994.

35. Hahn SH, Brantly ML, Oliver C, Adamson M, Kaler KG and Gahl WA. Methallothionien synthesis and degradation in Indian Childhoold Cirrhosis fibroblasts. Ped Res 35: 197-204, 1993.

36. Hahn SH, Krasnewich D, Brantly ML, Kvittingen EA and Gahl WA. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutration in an American child with chronic

tyrosinemia type I Human Mutation 1995; 6: 66-73.

37. Krasnewich DM, Holt GD, Brantly ML, Skovby F, Redwine, J and Gahl WA. Abnormal synthesis of dolichol-linked oligosaccharides in carbohydrate-deficient glycoprotein syndrome. Glycobiology 1995;5 :503-510.

38. Alpha- l-Antitrypsin deficiency registry study group. A registry of patients with severe deficiency of alpha- l-antitrypsin; Design and methods. Chest 1994; 106: 1223-1232.

39. Gouvea, V. and Brantly, M . Is Rotavirus a Population of Reassortants? Trends Microbiol 1995; 3: 159-162

40. McElvaney, NG., Stoller, JK., Buist, AS., Prakash, UBS., Brantly, M., Schluchter, M. and Crystal RG. Baseline characteristics of enrolles in the National Heart, Lung and Blood Institute registry of al-antitrypsin deficiency. Chest 1997; 111: 394-403.

41. Turino GL, Stoller J, Brantly ML, Barker A, Crystal RG, Cohen, A, Eden E. and Connelly R. Clinical and physiological characteristics of patients with the SZ phenotype of al-antitrypsin deficiency Am J Resp Crit Care Med 1996; 154: 1718-1725.

42. Brantly, M, Lee, JH , Hildeshiem, J, Prakash, UBS., Staats, BA and Crystal,.RG. al-Antitrypsin Gene Mutation Hotspot Associated with the Formation of a Retained and Degraded Null Variant. J Respir Cell Mol Biol 1997; 16: 225-231.

43. Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C-N., Finegold, M. and Grompe, M. Hepatocyctes corrected by gene therapy are selected in vivo in a murine model of Hereditary Tyrosinemia type I. Nature Genetics 1996; 12: 266-273.

44. WHO Report on al-Antitrypsin Deficiency. Pneumologie 1997 51: 885-918.

45. Combs, C., Brunt, EM., Solomon, H., Bacon, BR., Brantly, M., and Di Bisceglie, AM. Rapid development of hepatic alpha- l-antitrypsin globules after liver transplantation for chronic hepaptitis C. Gastroenterology 1997; 112: 1372-1375.

46. Stoller, J and Alpha- l-Antitrypsin deficiency registry study group Quality control of spirometry testing in the registry for patients with severe alpha l-antitrypsin deficiency Chest 1997, 111: 899-909.

47. Lee, JH., Novoradovskaya, N., Rundquist, B., Redwine, J., C. Saltini and Brantly, M. An alpha- l-antitrypsin nonsense mutation associated with a retained truncated protein and reduced mRNA. Lee, JH., Novoradovskaya, N., Rundquist, B., Redwine, J., C. and Brantly, M. Mol Genetics Metab 1998, 63: 270-280.

48. Novoradovskaya, N., JH. Lee and M. Brantly. Inhibition of intracellular degradation increases secretion of a mutant form of al-antitrypsin associated with profound deficiency. J. Clin Invest 1998, 101; 2693-2701.

49. Alpha- l-Antitrypsin deficiency registry study group. Survival and rate of FEV 1 decline in subjects enrolled in the NHLBI registry of patients with severe deficiency of alpha 1-antitrypsin Am J Resp Crit Care Med 1998, 158; 49-59.

50. Gahl WA, Brantly M, Kaiser-Kupfer MI, Iwata F, Hazelwood S, Shotelersuk V, Duffy LF, Kuehl EM, Troendle J, Bernardini I. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Eng J Med 1998,338: 12581264.

51. A. Novoradovsky, M. Brantly, P. Chaudhary, H. Ihara, L. Qi, NT. Eissa, P. Barnes, K. Gabriele, M. Ehrmantraut, and J. Moss. Endothelial nitric oxide synthase polymorphisms associated with obstructive lung disease in al-antitrypsin deficiency. Am J Resp Crit Care Med 1999,40: 441-447.

52. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne BJ, Atkinson M, Flotte TR. Sustained secretion of human alpha- l-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14384-8.

53. Paone G, Brantly, M. al-Antitrypsin Deficiency. Monaldi Arch Chest Dis 1998; 53: 606-608.

54. March, K., Sipes, D., Krause, M., Brantly, M., Trapnell, BT. Efficient In Vivo Cather-Based Pericardial Gene Transfer Using Adenoviral Vectors. Clin Cardiolgy 1999; 22:123-129, Suppl. 1 1999.

55. Brantly, M., N. A. Avila, V. Shotelersuk, C. Lucero, M. Huizing, and W. A. Gahl. 2000. Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest 117(1):129-36.

56. Virella-Lowell, I., A. Poirier, K. A. Chesnut, M. Brantly, and T. R. Flotte. 2000. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther 7(20):1783-9.

57. Stoller, J. K., M. Brantly, L. E. Fleming, J. A. Bean, and J. Walsh. 2000. Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency. Chest 118(3):843-8.

58. Rouhani, F., G. Paone, N. K. Smith, P. Krein, P. Barnes, and M. L. Brantly. 2000. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with alpha(1)-antitrypsin deficiency. Chest 117(5 Suppl 1):250S-IS.

59. Lee, J. H., and M. Brantly. 2000. Molecular mechanisms of alpha l-antitrypsin null alleles. Respir Med 94 Suppl C:S7-11.

60. Anikster, Y., F. Lacbawan, M. Brantly, B. L. Gochuico, N. A. Avila, W. Travis, and W. A. Gahl. 2001. Pulmonary dysfunction in adults with nephropathic cystinosis. Chest 119(2):394-401.

61. Stoller, J. K., F. Rouhani, M. Brantly, S. Shahin, R. A. Dweik, J. M. Stocks, J. Clausen, E. Campbell, and F. Norton. 2002. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 122(1):66-74.

62. Gahl, W. A., M. Brantly, J. Troendle, N. A. Avila, A. Padua, C. Montalvo, H. Cardona, K. A. Calis, and B. Gochuico. 2002. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 76(3):234-42.

63. Brantly, M. 2002. Alphal-Antitrypsin: Not Just an Antiprotease: Extending the Half-Life of a Natural Anti-Inflammatory Molecule by Conjugation with Polyethylene Glycol. Am J Respir Cell Mol Bio127(6):652-4.

64. Avila, N. A., M. Brantly, A. Premkumar, M. Huizing, A. Dwyer, and W. A. Gahl. 2002. Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol 179(4):887-92.

65. Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS, Fallat RJ, Stoller JK, Crystal RG, Turino GM. Asthma features in severe alphal-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest. 2003 Mar;123(3):765-71.

66. Spencer LT, Paone G, Krein P, Rouhani F, Rivera-Nieves J, Brantly M. The Role of Human Neutrophil Peptides in Lung Inflammation Associated with al-Antitrypsin Deficiency. American Journal of Physiology- Lung Cellular and Molecular Physiology 2004; 286(3):L514-520.

67. Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS, Fallat RJ, Stoller JK, Crystal RG, Turino GM. Asthma features in severe alphal-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest. 2003 Mar;123(3):765-71.

68. Strange, C., Dickson, R., Carter, C., Carpenter, M.J., Holladay, B., Lundquist, R., Brantly, M.L. Genetic Testing for Alphal-Antitrypsin Deficiency. Genetic Testing for Alphal-Antitrypsin Deficiency. In press Genetics in Medicine 2004.

69. M. Brantly, J. Wittes, C. Vogelmeier, R. Hubbard, G. Fells, and R. Crystal. Use of a Highly Purified al-Antitrypsin Standard to Establish Ranges for the Common Normal and Deficient al-Antitrypsin Phenotypes. Chest 1991 Sept; 100:703-708.

70. Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ, Humphries M. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Human Gene Therapy 2004 Jan; 15:93-128.

Abstracts

1. Brantly ML, Warner J. Pseudomonas putrefacians bacteremia: a case report and review of the literature. J. Virginia ACP 1982.
2. Paul L, Brantly M, Straus S, Dalgleish R, Courtney M, Tolstoshev P,LeCocq J-P, Crystal RG. Common polymorphisms of the al-antitrypsin gene not associated with alterations of protein isoelectric focusing patterns. Am Rev Respir Dis 1984; 129 (part 2): A306.

3. Brantly M, Paul L, Straus S, Dalgleish R, Courtney M, Tolstoshev P,LeCocq J-P, Crystal RG. Heterogeneity of al-antitrypsin gene sequences among individuals with the M phenotype. Clin Res 1984;32(2): 288A.

4. Nukiwa T, Brantly ML, Paul L, Garver R, Courtney M, Tolstoshev P, LeCocq JP, Crystal RG. Correlation of al-antitrypsin genotype assessed by gene specific oligonucleotide probes with al-antitrypsin protein phenotype. Am Rev Resp Dis 1985; 131 (part 2): A372.
5. Garver RI, Brantly ML, Paul LD, Nukiwa T, Courtney M, Tolstoshev P, LeCocq JP, Crystal RG. Structural analysis of the al-antitrypsin gene coding for the "null" haplotype. Am Rev Resp Dis 1985; 131 (part 2): A372.

6. Hirata T, Brantly M, Mornex J-F, Bitterman P, Crystal RG. Transferrin receptor gene expression during the maturation of blood monocytes to tissue macrophages. Clin Res 1985; 33(2): 379A

7. Nukiwa T, Brantly M, Paul L, Garver R, Courtney M, Tolstoshev P,LeCocq J, Crystal RG. Potential misdiagnosis using oligonucleotide probes to evaluate al-antitrypsin genotype in prenatal diagnosis. Clin Res 1985; 33(2): 331A

8. Garver R, Mornex J-F, Nukiwa T, Brantly M, Paul L, Courtney M, LeCoc J, Tolstoshev P, Crystal RG. al-antitrypsin deficiency associated with the absence of a detectable RNA transcripe of the al-antitrypsin gene. Clin Res 1985; 33(2): 464A

9. Curiel D, Garver R, Chytil-Weir A, Fells G, Stier L, Brantly M, Crystal R. The S variant of al-antitrypsin is associated with serum deficiency secondary to abnormal preglycosylation processing. Clin Res 1986;34(2): 575A.

10. Nukiwa T, Satoh K, Garver R, Brantly M, Crystal R. "Null" type al-antitrypsin deficiency associated with the homozygous inheritance of a nonsense (amber) mutation. Clin Res 1986; 34(2): 652A.

11. Brantly M, Nukiwa T, Stier L, Benavente A, Courtney M, Crystal R. In vitro demonstration of the molecular basis of the secretory defect associated with expression of the Z al-antitrypsin gene. Am Rev Respir Dis 1987; 135(4): A291

12. Garver R, Chytil A, Fells G, Brantly M, Courtney M, Crystal R. Retroviral gene transfer causes mouse fibroblasts to secrete normal human alpha al-antitrypsin. Am Rev Respir Dis 1987; 135(4): A339.

13. Nukiwa T, Brantly M, Ogushi F, Fells G, Satoh K, Stier L, Courtney M, Crystal R. Characterization of the M1(ala213) type of a1-antitrypsin, a newly recognized, common "normal" al-antitrypsin haplotype. Am Rev Respir Dis 1987; 135(4): A291.

14. Satoh K, Takahashi H, Nukiwa T, Brantly M, Garver R, Courtney M, Crystal R. Molecular basis of the "null" state of al-antitrypsin deficiency. Am Rev Respir Dis 1987; 135(4): A292.

15. Takahashi H, Nukiwa T, Ogushi F, Brantly M, Courtney M, Crystal R. Identification and molecular analysis of a new variant of al-antitrypsin characterized by marked reduction of serum levels. Am Rev Respir Dis 1987; 135(4): A292.

16. Moller D, Konishi K, Saltini C, Spurzem J, Brantly M, Balbi B, Madoo L, Crystal RG. Persistent and similar rearrangements of the T-cell antigen receptor b-chain gene are present in populations of lung and blood T-cells among individuals with pulmonary sarcoidosis. Clin Res 1987; 35: 632A.

17. Curiel D, Brantly M, Curiel E, Stier L. Crystal R. al-Antitrypsin deficiency caused by al-antitrypsin null mattawa: An insertion mutation rendering the al-antitrypsin gene incapable of producing al-antitrypsin. Am Rev Respir Dis 1988; 137(4): 210.

18. Brantly ML, Nukiwa T, Ogushi F, Fells GA, Stier L, Crystal RG. Gene and protein characteristics of the common normal al-Antitrypsin variant M2. Am Rev Respir Dis 1988; 137(4): 209.

19. Brantly ML, States DJ, Courtney M, Crystal RG. Evidence for complex electrostatic interactions associated with a critical salt linkage in the al-antitrypsin protein. J Cell Biol 1988; 107(6):834A.

20. Curiel D, Chytil A, Brantly ML, Stier L, Okayama H, Courtney M, Crystal RG. Use of retroviral gene transfer to characterize the molecular pathophysiologic mechanisms underlying al-antitrypsin deficiency. J Cell Biol 1988; 107(6):834A.

21. Holmes M, Curiel D, Brantly ML, Crystal RG. Characterization of the intracellular mechanism causing the al-antitrypsin Nullgranite falls deficiency state. Am Rev Respir Dis 1989; 139:A202.

22. Holmes M, Brantly ML, Wurts L, Crystal RG. Characterization of the sequence differences among the P-family of al-antitrypsin alleles. Am Rev Resp Dis 1989; 139: A369.

23. Laubach V, Curiel D, Brantly ML, Holmes M, Crystal RG. Characterization of the gene sequence of the common al-antitrypsin normal M3 allele. Am Rev Respir Dis 1989; 139: A368.

24. Okayama H, Curiel D, Brantly ML, Holmes M, Crystal RG. Rapid, nonradioactive analysis of mutations in the al-antitrypsin gene by allele specific amplication. Am Rev Respir Dis 1989; 139: A201.

25. Curiel D, Holmes M, Okayama H, Travis W, Stier L, Brantly M, Crystal RG. Molecular basis of liver disease associated with al-antitrypsin deficiency. Clin Res 1989; 37 (2): 366A.

26. Laubach V, Hildesheim J, Ryan WJ, Brantly M. al-antitrypsin Nullwest: absence of detectable serum al-antitrypsin as a result of a point mutation in a mRNA splice donor site. Am J Hum Genetics 1991; 49: A411.

27. Hildesheim J, Kinsley G, Bissell M, Pierce J, Brantly M. al-antitrypsin Pduarte: Heterogeneity of P-Family alleles resulting from gene mutations on different background alleles. Am J Hum Genetics 1991; 49: A491.

28. Birrer P, Rundquist B, Wirz Sommer C, Brantly M. Establishment of an accurate normal range of serum al-antitrypsin concentration in cord blood of healthy newborns. Am Rev of Respir Dis 1992 145: A342..

29. Brantly ML, Hildeshiem J, Laubach V, Rundquist B, Lester Paul. al-Antitrypsin Nullnew hope: Natural Conversion of the al-Antitrypsin Deficiency Z Variant into a Null Variant by the Addition of Second Amino Acid Substitution. Clin. Res. 1992; 40:328A.

30. M. Brantly, V. Laubach, J. Hildesheim, J. Leifer, J. Redwine, N. Mittereder, B. Trapnell. Intron sequence dependent enhancement of al-antitrypsin gene expression. Cold Spring Harbor Laboratory 1993.

31. Mahaney K, Brantly ML, Redwine J, Hoofnagle, JH and Di Bisceglie AM. Alpha- l-antitrypsin levels and phenotypes and progression of liver disease in chronic viral hepatitiis. Hepatology 1993 .

32. Hahn SH, Brantly ML, Chou J, Krasnewich DM, Kvittingen, EA and Gahl WA. Mutation analysis of the Fumarylacetoacetate hydrolase gene in an American boy with tyrosinemia type 1: Retrovirus-mediated transfer of recombinant FAH gene to the mutant fibroblast. 1994

33. Novoradovskaya N. and Brantly M. The major mechanism for al-antitrypsin deficiency is intracellular degradation of Z al -antitrypsin. Resp Crit Care Med. 1995; 151: A533.

34. Lee JH, Novoradovskaya N, Saltini C, Ong S and Brantly M. QO trastevere: an *al*-antitrypsin null variant associated with reduced rnRNA expression and intracellular protien degradation. J Invest Med 1995; 43: 275A.

35. Woody, M., Mehdi, K., Zipes, DP., Brantly, M., Trapnell, BT., March, KL. High efficiency adenovirus-mediated pericardial gene transfer in vivo.Circulation 1995

36. Lee, J.,and Brantly, M. A conformational change in the reactive site loop of al-antitrypsin promotes rapid intracellular degradation. J Invest Med 1996: 270A.

37. Lee, JH. Novoradovskaya, N and Brantly, M. Intracellular fates of null variants with termination codons near the hinge region of the active site loop of al-antitrypsin. Am J Respir Crit Care Med 1996; 153: 400A.

38. Gabriele, K, Barnes, P., Lew, J. and Brantly, M. Evaluation of the relationship of serum IgE and reactive airways disease in al-antitrypsin deficient individuals. Am J Respir Crit Care Med 1996; 153: 822A.

39. Novoradovskaya, N., Lee, JH. and Brantly, M. The affect of increased temperture and cyclohexamide on inhibition of intracellular degradation and secretion of Z al-antitrypsin. Am J Respir Crit Care Med 1996; 153: 400A.

40. W.A. Gahl, M. Brantly, F. Rhouhani, J. Guo, G. Holt, R. Willis, K. Folkers. Clinical and laboratory findings in Hermansky-Pudlak Syndrome (BPS) Am J Hum Genetics 1996; 59: A198.

41. N. Novoradovskaya, JH. Lee and M. Brantly. A new approach to treatment of al-antitrypsin deficiency: inhibition of intracellular degradation using proteasome inhibitors. Am J Resp Crit Care Med 1997; 155: A653.

41. G. Paone, F. Rouhani and M. Brantly. Potential role of human neutrophil defensins in lung destruction in individuals with al-antitrypsin deficiency. Am J Resp Crit Care Med 1997; 155: A835.

43. F. Rouhani, N.K. Smith, K. Gabriele, P. Barnes, G. Paone and M. Brantly. Factors associated with early lung destruction in al-antitrypsin deficient individuals with mild lung function abnormalities. Am J Resp Crit Care Med 1997; 155: A835.

44. P. Barnes, K. Gabriele, G. McElvany, F. Rouhani and M. Brantly. The relationship of lower respiratory tract neutrophil burden and reactive airways disease in al-antitrypsin deficient individuals. Am J Resp Crit Care Med 1997; 155: A592.

45. JH. Lee, F. Rouhani, J. Rivera and M. Brantly. Structural based mechanism for the formation of functionally inactive al-antitrypsin following large scale purification. Am J Resp Crit Care Med 1997; 155: A562.

46. N. Novoradovskaya, JH. Lee, and M. Brantly. Multiple mechanisms of intracellular degradation contribute to Z a 1- antitrypsin catabolism. Am J Resp Crit Care Med 1998; 157: A571.

47. A. Novoradovsky, M. Brantly, P. Chaudhary, H. Ihara, L. Qi, NT. Eissa, P. Barnes, K. Gabriele, M. Ehrmantraut, and J. Moss. Endothelial nitric oxide synthase polymorphisms associated with obstructive lung disease in a 1-antitrypsin deficiency. Am J Resp Crit Care Med 1998; 157: A234.

48. G. Paone, P. Krein, F. Rouhani, N.K. Smith, and M. Brantly. The role of human neutrophil peptides in neutrophil accumulation in individuals with a 1-antitrypsin deficiency. Am J Resp Crit Care Med 1998 ; 157: A194.

49. M. Brantly, F. Rouhani, C. Jolley, S. Hazelwood, V. Shotelersuk, S. Chen, and WA. Gahl. Increased risk of pulmonary fibrosis in puerto rican individuals with a 16-bp duplication in the hermansky-pudlak syndrome gene. Am J Resp Crit Care Med 1998 ; 157: A494.

50. F. Rouhani, G. Paone, NK. Smith, P. Krein, P. Barnes, and M. Brantly. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with a 1-antitrypsin deficiency. Am J Resp Crit Care Med 1998; 157: A194.

51. JH. Lee, N. Novoradovskaya and M. Brantly. Oxidants alter the structure of a 1-antitrypsin. Am J Resp Crit Care Med 1998 ; 157: A194.

52. …… (In Press)

53. …… (In press)

54. …….. (In press)

55. ……(In press)

56. ……

…….. (In press)

57. N. Novoradovskaya, JH Lee and M. Brantly. Secretion of a misfolded form of alpha- l-antitrypsin is regulated by post-translational processing. Mol Cell Bio 1998; 9: A460.

58. …… …… ….. (In press)

Book Chapters

1. Hubbard RC, Brantly ML, Crystal RG. Proteases. In The Lung: Scientific Foundations, ed. Crystal RG, West JB. Raven Press, Ltd., New York pp 1775-1788, 1991

2. Hubbard RC, Brantly ML, Crystal RG. Proteases. In Lung Injury, ed. Crystal RG, West JB. Raven Press, Ltd., New York pp 3-13, 1992.

3. Brantly M. Laboratory diagnosis of al-antitrypsin deficiency. In Alpha- l-Antitrypsin Deficiency, Crystal, RG. ed. 1995, Marcel Dekker, New York, pp. 45-60.

4 Brantly M. al-antitrypsin phenotypes and genotypes. In Alpha- l-Antitrypsin Deficiency, Crystal, RG. ed. 1995, Marcel Dekker, New York, pp. 211-226.

5. Saltini, CS and M. Brantly. Beryllium Disease. In Pulmonary Diseases; Clinical Medicine Series, Grassi, C. ed 1999, McGraw Hill, Berkshire, pp. 283-287.

Patents

Increased Expression of Alpha- l-Antitrypsin in Expression Vectors Through the inclusion of Intron II. Patent Serial Number 08/060,925

Clinical Studies Last 10 years

1. Armour Al-PI Intravenous Phase la, (NIH, Bethesda, Maryland) 1995-6
PI and Central Lab for study
2. Alpha Therapeutics AIPI Intravenous Phase III (NIH, Bethesda, Maryland, University of Florida) 1995-2000.
Central Lab for study

3. Armour-Centeon Al-PI Intravenous Phase Ib (NIH and University of Florida), 1998-1999.
Central Lab for study

4. PPL Aerosolized Transgenic Sheep Alpha- l-Antitrypsin Phase I/Pilot (University of Florida) 1999-2000, PI and central lab
5. Centeon -Aventis-Behring Phase III Intravenous Phase III (University of Florida) PI and Central Lab, 2000-2001
6. Aventis-Behring Phase I Aerosolized A1-PI (University of Florida) 2000-2001 PI and Central Laboratory
7. American Red Cross- Phase I Intravenous AIPI, (University of Florida) Ongoing PI and Central Lab
8. Baxter-Arriva-Phase I Aerosolized rAAT (University of Florida) Ongoing PI
9. Alpha One Foundation - 4-Phenyl butyrate Secretion Rescue (University of Florida) Ongoing, PI and Central Laboratory